T0U0 Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
TC Biopharm (Holdings) Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.25 |
| 52 Week High | US$110.00 |
| 52 Week Low | US$6.50 |
| Beta | 0.11 |
| 11 Month Change | 0% |
| 3 Month Change | 6.45% |
| 1 Year Change | -86.86% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| T0U0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.2% | -1.9% |
| 1Y | -86.9% | -9.8% | 12.3% |
Return vs Industry: T0U0 underperformed the German Biotechs industry which returned -9.8% over the past year.
Return vs Market: T0U0 underperformed the German Market which returned 12.3% over the past year.
Price Volatility
| T0U0 volatility | |
|---|---|
| T0U0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: T0U0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine T0U0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 41 | Bryan Kobel | tcbiopharm.com |
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
TC Biopharm (Holdings) Plc Fundamentals Summary
| T0U0 fundamental statistics | |
|---|---|
| Market cap | €3.79m |
| Earnings (TTM) | -€10.28m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs T0U0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| T0U0 income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£8.59m |
| Earnings | -UK£8.59m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -15.68 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did T0U0 perform over the long term?
See historical performance and comparison